Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira (R) lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3)

AIRFLOW-3 Trial Study Grp, 13-Feb-2020, In : BMC Pulmonary Medicine. 20, 1, 10 p., 41.

Research output: Contribution to journalArticleAcademicpeer-review

  • AIRFLOW-3 Trial Study Grp

Background Targeted lung denervation (TLD) is a bronchoscopically delivered ablation therapy that selectively interrupts pulmonary parasympathetic nerve signaling. The procedure has the potential to alter airway smooth muscle tone and reactivity, decrease mucous secretion, and reduce airway inflammation and reflex airway hyperresponsiveness. Secondary outcome analysis of a previous randomized, sham-controlled trial showed a reduction in moderate-to-severe exacerbations in patients with COPD after TLD treatment. A pivotal trial, AIRFLOW-3 has been designed to evaluate the safety and efficacy of TLD combined with optimal medical therapy to reduce moderate or severe exacerbations throughout 1 year, compared with optimal medical therapy alone. Methods The study design is a multicenter, randomized, full sham bronchoscopy controlled, double-blind trial that will enroll 400 patients (1:1 randomization). Key inclusion criteria are FEV1/FVC <0.7, FEV1 30 to 60% of predicted, post-bronchodilator, >= 2 moderate or 1 severe COPD exacerbations in the prior year, and COPD assessment test (CAT) >= 10. Primary objective will be the comparison of moderate or severe COPD exacerbations through 12 months of TLD therapy with optimal medical therapy versus optimal medical therapy alone. The sham group will be allowed to cross over at 1 year. Patients will be followed for up to 5 years. Discussion The multicenter, randomized, full sham bronchoscopy controlled, double-blind AIRFLOW-3 trial will evaluate the efficacy of TLD to reduce moderate or severe COPD exacerbations beyond optimal medical therapy alone. The target population are patients with COPD, who suffer persistent symptoms and exacerbations despite optimal treatment, defining an unmet medical need requiring novel therapeutic solutions. This trial is registered at : NCT03639051.

Original languageEnglish
Article number41
Number of pages10
JournalBMC Pulmonary Medicine
Issue number1
Publication statusPublished - 13-Feb-2020


  • COPD, Nerves, Targeted lung denervation, Acetylcholine, Anticholinergic, Bronchoscopy, EXACERBATIONS, PREVENTION, TIOTROPIUM

Download statistics

No data available

ID: 121028183